Results 111 to 120 of about 5,903 (227)

Advances in Immunological Combination Therapy for Colorectal Cancer

iMetaMed, Volume 2, Issue 3, September 2026.
Review the progress of combined immunotherapy for colorectal cancer. ABSTRACT Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration.
Jiayue Wu, Rongbo Wen, Tianshuai Zhang, Fuao Cao, Xiaoming Zhu, Liqiang Hao, Wei Zhang, Guanyu Yu   +7 more
wiley   +1 more source

The correlation between DPYD9A (c.85T > C) genotype and dihydropyrimidine dehydrogenase deficiency phenotype in patients with gastrointestinal malignancies treated with fluoropyrimidines: Updated analysis

, 2019
544 Background: The correlation between DPYD*9A (c.85T > C) genotype and dihydropyrimidine dehydrogenase (DPD) deficiency phenotype is controversial.
Hosein, Peter Joel, Patel, Girijesh K, Frankel, Arthur E, Singh Maharjan, Anu, Khushman, Moh'd M, Awan, Saad, Taylor, William R, Pai, Sachin, Wang, Bin, McMillin, Gwendolyn A, Nelson, Cindy, Singh, Ajay   +11 more
core   +1 more source

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 792-802, September 2026.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli, Cecilia Catapano, Iacopo Ghini, Mariateresa Rossi, Marina Venturini, Valeria Boccaletti   +5 more
wiley   +1 more source

Advances in therapeutic approaches to gastric cancer

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract Gastric cancer remains a leading cause of cancer‐related mortality worldwide, with nearly 1 million new cases diagnosed annually. Despite innovations in diagnosis, most patients still present at advanced stages, contributing to a poor prognosis.
Feng Wang, Zi‐Xian Wang, Yu‐Jing Zhang, Ye He, Jia‐Fu Ji, Yuan‐Fang Li, Xiu‐Juan Qu, Yi Ba, Shu‐Qiang Yuan, Rui‐Hua Xu   +9 more
wiley   +1 more source

The Conundrum of Cancer-Associated Thrombosis: Lesson Learned from Two Intriguing Cases and Literature Review

Diseases
The correlation between cancer and venous thromboembolism (VTE) is solid, whereas the knowledge about cancer-related arterial thromboembolism (ATE) still needs a deeper investigation to clarify its pathogenesis.
Simona Laurino, Sabino Russi, Ludmila Carmen Omer, Alberto D’Angelo, Giovanni Bozza, Giuseppina Gallucci, Geppino Falco, Giandomenico Roviello, Anna Maria Bochicchio   +8 more
doaj   +1 more source

Cardiovascular safety of 5-fluorouracil and capecitabine in colorectal cancer patients: real-world evidence

Cardio-Oncology
Background Fluoropyrimidines, including 5-fluorouracil and capecitabine, are the most common chemotherapeutic agents for colorectal carcinoma. Although previous studies have suggested varying degrees of cardiotoxicity with these drugs, there is a notable
Chun-Ka Wong, Isaac Ho, Ali Choo, Rachel Lau, Ting-Fung Ma, Alston Conrad Ho-On Chiu, Tsun-Ho Lam, Minqing Lin, Ricky Wang-Hei Leung, Frankie Chor-Cheung Tam, Dominic Chi Chung Foo, Hung-Fat Tse   +11 more
doaj   +1 more source

Exploring additional mechanisms of cell injury by fluoropyrimidines in the treatment of cancer: an investigation of novel protide NUC-3373

, 2019
5-Fluorouracil (5-FU) has been the backbone of chemotherapy for solid tumours such as colorectal cancer (CRC) for over 60 years. Despite advances in combinatorial treatments, most patients experience innate or acquired resistance to 5-FU as well as ...
McKissock, Fiona Grace
core   +1 more source

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

, 2008
Purpose We conducted a retrospective analysis of safety data from randomized, single-agent fluoropyrimidine clinical trials ( bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to test the hypothesis that there are regional differences in ...
Gilberg, F., Bertino, J. R., Saltz, Leonard B, Van Cutsem, E., Rustum, Y., O'Connell, Michael, Allegra, C., Rustum, Youcef, Gustavsson, Bengt,, Tabernero, Josep, Saltz, L. B., Allegra, Carmen, Schmoll, H.-J., Douillard, J.-Y., O'Connell, M., Clarke, Stephen J, Twelves, C., Sirzén, Florin, Hoff, P. M., Sirzen, F., Cunningham, David, Bertino, Joseph R, Gilberg, Frank, Cassidy, J., Van Cutsem, Eric, Douillard, Jean-Yves, Rothenberg, Mace L, Haller, D. G., Milano, G., Twelves, Chris, Cunningham, D., Milano, Gerard, Gustavsson, B. G., Tabernero, J., Haller, Daniel G, Rothenberg, M. L., Cassidy, Jim, Schmoll, Hans-Joachim, Clarke, S. J., Hoff, Paulo M   +39 more
core   +1 more source

Fluoropyrimidine [PDF]

, 2020
openaire   +1 more source

The Prevalence of DPYD9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis

, 2019
The dihydropyrimidine dehydrogenase gene (DPYD)*9A (c.85T>C) genotype is relatively common. The correlation between DPYD*9A genotype and dihydropyrimidine dehydrogenase (DPD) deficiency phenotype is controversial.
Hosein, Peter Joel, Frankel, Arthur E, Singh, Ajay P, Awan, Saad, Patel, Girijesh Kumar, Taylor, William R, Pai, Sachin, Wang, Bin, Maharjan, Anu Singh, Khushman, Moh’d, McMillin, Gwendolyn A, Nelson, Cindy   +11 more
core   +1 more source